title: Left ventricular hypertrophy precedes other target-organ damage in primary aldosteronism.
abstract: To elucidate whether there is a difference in the progression of target-organ damage between primary aldosteronism and essential hypertension, we compared left ventricular hypertrophy and extracardiac target-organ damage in 23 patients with primary aldosteronism and 116 patients with essential hypertension. The severity of hypertensive retinopathy and the renal involvement in primary aldosteronism were subclinical and similar to those in essential hypertension without left ventricular hypertrophy but significantly milder than those in essential hypertension with left ventricular hypertrophy. There was a strongly significant correlation between the degree of left ventricular mass index and the severity of hypertensive retinopathy and renal involvement independent of office blood pressure in essential hypertension. In contrast, left ventricular hypertrophy markedly progressed despite the mild extracardiac target-organ damage in primary aldosteronism. Left ventricular end-diastolic dimension index in primary aldosteronism (3.16+/-0.50 cm/m2) was significantly larger than in essential hypertension without (2.87+/-0.23) and with (2.88+/-0.22) left ventricular hypertrophy. On the other hand, there was no difference in extracardiac target-organ damage between 13 primary aldosteronism patients with eccentric left ventricular hypertrophy and the 26 essential hypertensive patients with eccentric left ventricular hypertrophy. The results suggest that predominantly volume load, be it due to aldosteronism or other mechanisms, resulting in eccentric left ventricular hypertrophy is less likely to cause extracardiac target-organ damage than hemodynamic or nonhemodynamic mechanisms resulting in concentric left ventricular hypertrophy.
authors.affiliation: The Second Department of Internal Medicine, Ehime, University School of Medicine, Shige-nobu-cho, Onsen-gun, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Shigematsu
authors.forename: M
authors.initials: M
authors.lastname: Hamada
authors.forename: H
authors.initials: H
authors.lastname: Okayama
authors.forename: Y
authors.initials: Y
authors.lastname: Hara
authors.forename: Y
authors.initials: Y
authors.lastname: Hayashi
authors.forename: K
authors.initials: K
authors.lastname: Kodama
authors.forename: K
authors.initials: K
authors.lastname: Kohara
authors.forename: K
authors.initials: K
authors.lastname: Hiwada
mesh_terms: D000328:Adult; D000368:Aged; D000450:Aldosterone / Q000494:pharmacology; D004562:Electrocardiography; D005260:Female; D006801:Humans; D006929:Hyperaldosteronism / Q000150:complications* / Q000503:physiopathology*; D006973:Hypertension / Q000150:complications* / Q000503:physiopathology*; D017379:Hypertrophy, Left Ventricular / Q000150:complications* / Q000503:physiopathology*; D008297:Male; D008875:Middle Aged
chemical_list: D000450:Aldosterone